GRM3 Antibody, FITC conjugated

1. experiments indicate that mGlu3Delta4 may negatively modulate mGlu3, and thereby impact on the roles of GRM3/mGlu3 in schizophrenia and as a therapeutic target PMID: 28655286
2. Our findings support the GWAS-implicated link between GRM3 genetic variation and schizophrenia risk as well as the notion that alleles conferring this risk may be population specific. PMID: 28786982
3. Results demonstrate that GRM3 expression is significantly upregulated in human colonic adenocarcinomas and colon cancer cell lines. This upregulation is mediated at the post-transcriptional level where miR-487b directly targets GRM3 to suppress its translation. Also, the fact that TGFbeta increases GRM3 protein stability provide novel mechanisms of post-transcriptional regulation of GRM3 in colon cancer. PMID: 28114282
4. Low GRM3 expression is associated with multiple myeloma and B-cell leukemia. PMID: 27431857
5. Significant association was found between rs12704290 in GRM3 gene and schizophrenia(SCZ). A three-SNP LD spanning GRM3Delta4 splice site was significantly associated with SCZ. Interaction between the LD block and cognitive function was found in SCZ patients. PMID: 26187343
6. Results show that GRM3 rs274622 C carriers with schizophrenia were associated with significantly smaller prefrontal activation than patients with TT genotype PMID: 25914064
7. Grm3 expression was decreased in B cells from patients with autoimmune diseases such as activated systemic lupus erythematosus and multiple sclerosis. PMID: 26071318
8. Pharmacogenetic relationships were identified in patients with schizophrenia between GRM3 variants and symptom response to antipsychotics. PMID: 25096017
9. PI4KA and GRM3 polymorphisms have potential to jointly modulate antipsychotic response PMID: 25209194
10. The mGluR3 promoted the proliferation of human embryonic cortical NPCs and increased cyclin D1 expression by activating ERK1/2 and JNK2 signaling pathways. PMID: 25198581
11. The data of this study suggest an association of the GRM3 rs6465084 polymorphism with changes in pursuit maintenance after antipsychotic treatment. PMID: 24682224
12. This study provided that the evidence for an association between GRM3 genotype and schizophrenia and suggest a role for glutamate neurotransmission in the establishment and maintenance of myelinated fibers. PMID: 24680030
13. results supplied the first evidence that the polymorphism of GRM3 gene associates with the morbidity of alcohol dependence in human beings. PMID: 24585043
14. report we describe a novel neuroprotective function of mGlu3 receptors related to their ability to promote the non-amyloidogenic pathway of APP cleavage in astrocytes, thus enhancing sAPPalpha production PMID: 24291464
15. Data indicate that metabotropic glutamate receptor subtype 3 (mGluR3) polymorphisms do not contribute to genetic susceptibility to schizophrenia and depression, but they confer an increased risk of heroin dependence (HD) in a Chinese population. PMID: 24498053
16. The transcript of mGlu3 receptors should be measured in tumor specimens for a correct prediction of patients' survival in response to temozolomide treatment. PMID: 23175182
17. Kozak sequence variant associated with bipolar disorder PMID: 23575746
18. glutamate system dysfunction may play a role in the prefrontal functional abnormalities seen in alcoholism. certain GRM3 SNP genotypes may further lower NAA/Cr levels and executive function in addition to the effect of alcohol. PMID: 22909248
19. Polymorphisms in the GRM3 gene may be associated with refractory global psychosis symptoms but not negative symptoms in persons with schizophrenia. PMID: 21344500
20. analysis suggested that mGluR3 is the major mGlu receptor expressed by adult cortical astrocytes, whereas the expression of other mGluRs was low or absent PMID: 23307741
21. These results suggest that variations in GRM3 genotype modulate the auditory cortical response to phoneme change in humans. PMID: 22022368
22. Melanoma cells expressing mutant GRM3 had reduced cell growth and cellular migration after short hairpin RNA-mediated knockdown of GRM3 or treatment with a selective MEK inhibitor, AZD-6244, which is currently being used in phase 2 clinical trials PMID: 21946352
23. This study suggested a gene-environment (G x E) interaction between GRM3 gene variants and severe obstetric complications on hippocampus volume, independent of a diagnosis of schizophrenia. PMID: 20638435
24. Findings strongly suggest that the genetic variation (rs17676277 and three haplotypes) in the metabotropic glutamate receptor 3is related to cognitive setshifting in healthy individuals independent of working memory. PMID: 20132315
25. An association is found between one marker (rs6465084) in glutamate receptor gene GRM3 and Japanese patients with major depressive disorder. PMID: 19386277
26. results define a microenvironment within the binding pocket that encompasses several positively charged amino acids that recognize the negatively charged phosphonate group of l-AP4 or the endogenous compound l-serine-O-phosphate. PMID: 11744707
27. genetic variation in the metabotropic glutamate receptor 3 gene that might contribute to genetic predisposition to schizophrenia and/or bipolar affective disorder PMID: 11840505
28. At least one susceptibility locus for schizophrenia is situated within or very close to the GRM3 region in Japanese patients. PMID: 12782962
29. mGluR3 and mGluR5 can critically and differentially modulate the expression of glutamate transporters and may represent interesting pharmacological targets to regulate the extracellular levels of glutamate in pathological conditions. PMID: 12786977
30. glial progenitor cells present in the adult human CNS express mGluR3 and mGluR5a PMID: 15158450
31. definition of the essential requirements for ligand binding to the extracellular domain of mGluR3 and highlight parameters important for the optimization of receptor expression in mammalian cells PMID: 15178451
32. Reduction of mGluR3 immunopositive product in the stratum lacunosum moleculare of hippocampal CA1 is a consequence of neuronal loss in either the entorhinal cortex or CA1 area of the hippocampus. PMID: 15246118
33. Data point to a specific molecular pathway by which metabotropic glutamate receptor GRM3 alters glutamate neurotransmission, prefrontal and hippocampal physiology and cognition, and thereby increased risk for schizophrenia. PMID: 15310849
34. MGluR3 modulate the release of IL-6 in the presence of IL-1beta, supporting the role of mGluR3 in the regulation of the inflammatory and immune response associated with gliosis. PMID: 15652990
35. GRM3 polymorphism may be associated with negative symptom improvement in persons with schizophrenia treated with olanzapine. PMID: 15913960
36. The existence of the GRM3Delta4 isoform is relevant in the light of the reported association of non-coding single nucleotide polymorphisms (SNPs) in GRM3 with schizophrenia. PMID: 16417579
37. SNPs in RGS4, G72, GRM3, and DISC1 showed evidence for significant statistical epistasis with COMT. PMID: 17006672
38. mGlu3 receptor levels are altered in schizophrenia PMID: 17531207
39. extend putative brain dopaminergic and glutamatergic relationships indexed by catechol-O-methyltransferase and GRM3 to a systems-level interaction in human cortical circuits implicated in working memory dysfunction such as in schizophrenia PMID: 17636131
40. we genotyped rs274622 in the promoter region of GRM3. In the present study, none of these polymorphisms were associated with schizophrenia PMID: 17948896
41. Single nucleotide polymorphisms are not assoiated with schziphrenia. PMID: 18075480
42. The study of DNA sequence variants in the GRM3 gene did not provide further support for genetic association with schizophrenia or for correlation with cognitive deficits. PMID: 18197082
43. An exon 3 single nucleotide polymorphism (SNP) in GRM3 predicts increased splicing of the fourth exon and may contribute to risk for schizophrenia by modulating GRM3 splicing. PMID: 18256595
44. The results of the present study indicate that the rs6465084 functional polymorphism in GRM3 does not contribute to genetic susceptibility to schizophrenia. PMID: 18412850
45. these data implicate mGluR3 in aetiological, pathophysiological and pharmacotherapeutic aspects of schizophrenia--REVIEW PMID: 18541626
46. Our results provide further evidence for the potential importance of the glutamate receptor GRM3 in schizophrenia, and indicate that the novel antipsychotic LY2140023 may actually be targeting a pathogenic pathway of schizophrenia. PMID: 18614340
47. These data suggest that Glutamate receptor metabotropic 3 glutamate metabotropic receptor is disrupted in the AH in schizophrenia and localize the defect to the CA1 and CA3 regions. PMID: 19403271
48. present Scandinavian results do not verify previous associations between the analyzed DTNBP1, NRG1, DAO, DAOA, and GRM3 gene polymorphisms and schizophrenia PMID: 19439994

Show More

Hide All

HGNC: 4595

OMIM: 601115

KEGG: hsa:2913

STRING: 9606.ENSP00000355316

UniGene: Hs.590575